Illumina (ILMN) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4523271090

Sequencing Instruments, Genomic Analysis Kits, Whole-Genome Sequencing Kits

Illumina, Inc. is a pioneer in the field of genetic and genomic analysis, offering a comprehensive range of sequencing- and array-based solutions to researchers, clinicians, and consumers worldwide. With a strong presence in the United States, Singapore, the United Kingdom, and internationally, the company operates through two main segments: Core Illumina and GRAIL.

The company's innovative products and services include sequencing and array-based instruments and consumables, such as reagents, flow cells, and library preparation, which enable scientists to analyze genetic data with unprecedented precision and accuracy. Its whole-genome sequencing kits can sequence entire genomes of various sizes and complexities, while targeted resequencing kits focus on specific genes, RNA, or genomic regions of interest.

Illumina's portfolio also includes a range of services, including whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support. The company's flagship product, Galleri, is a groundbreaking multi-cancer early detection test that has the potential to revolutionize cancer diagnosis and treatment. Additionally, Illumina is developing cutting-edge solutions to accelerate cancer diagnoses, detect minimal residual disease through blood-based testing, and enable other post-diagnostic applications.

The company's customer base is diverse and global, comprising genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical companies, biotechnology firms, commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina markets and distributes its products directly to customers, as well as through a network of life-science distributors.

Founded in 1998 and headquartered in San Diego, California, Illumina, Inc. is a leader in the genomics industry, driving innovation and advancing our understanding of the human genome. To learn more, visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Illumina (ILMN) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Illumina (ILMN) - Stock Price & Dividends

ILMN Stock Overview

Market Cap in USD 18,274m
Sector Healthcare
Industry Diagnostics & Research
GiC SubIndustry Life Sciences Tools & Services
TER 0.00%
IPO / Inception 2000-07-28

ILMN Stock Ratings

Growth 5y -61.7
Fundamental 7.01
Dividend -
Rel. Performance vs Sector -7.40
Analysts 3.65/5
Fair Price Momentum 85.47 USD
Fair Price DCF 62.80 USD

ILMN Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

ILMN Growth Ratios

Growth 12m -46.16%
Growth Correlation 12m -50%
Growth Correlation 3m -69%
CAGR 5y -21.17%
CAGR/Mean DD 5y -0.54
Sharpe Ratio 12m -1.26
Alpha vs SP500 12m -74.66
Beta vs SP500 5y weekly 1.05
ValueRay RSI 64.04
Volatility GJR Garch 1y 43.44%
Price / SMA 50 -4.41%
Price / SMA 200 -13.74%
Current Volume 35653.2k
Average Volume 20d 4314.8k

External Links for ILMN Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of ILMN stocks?
As of June 22, 2024, the stock is trading at USD 108.57 with a total of 35,653,154 shares traded.
Over the past week, the price has changed by -0.08%, over one month by +0.89%, over three months by -21.01% and over the past year by -45.68%.
What are the forecast for ILMN stock price target?
According to ValueRays Forecast Model, ILMN Illumina will be worth about 95 in June 2025. The stock is currently trading at 108.57. This means that the stock has a potential downside of -12.54%.
Issuer Forecast Upside
Wallstreet Target Price 148.7 37.0
Analysts Target Price 186.4 71.7
ValueRay Target Price 95 -12.5